Ovarian cancer patients with localized relapse: Clinical outcome and prognostic factors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Ovarian cancer patients with localized relapse: Clinical outcome and prognostic factors

Published:2013-10 Issue:1 Volume:131 Page:36-41
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Petrillo M.,Fagotti A.,Ferrandina G.,Fanfani F.,Costantini B.,Vizzielli G.,Pedone Anchora L.,Nero C.,Margariti P.A.,Scambia G.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference23 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013

2. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer;Heintz;Int J Gynaecol Obstet,2006

3. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin;Markman;J Clin Oncol,1991

4. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design;Markman;J Clin Oncol,2004

5. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [see comments];Eisenhauer;Ann Oncol,1997

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Robotic approach for the treatment of gynecological cancers recurrences: A ten-year single-institution experience;European Journal of Surgical Oncology;2024-09

2. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor: A Single-Institution Experience (ID: PARROT Trial);Annals of Surgical Oncology;2023-12-15

3. Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer;World Journal of Surgical Oncology;2023-11-30

4. Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer;Cancers;2023-09-28

5. PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients;Gynecologic Oncology;2023-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3